Aspire Biopharma Holdings, Inc.
A biopharmaceutical company developing a sublingual (under-the-tongue) drug delivery platform that lets medications and supplements absorb quickly into the bloodstream, skipping the stomach and liver. Founded in 2021, it came to life when the earlier shell company PowerUp Acquisition Corp. merged with it in early 2025 and the combined business took the name Aspire. The name "Aspire" nods to ambition, though the company has never spelled out a story behind it—a small mystery fans of naming lore can chew on.
Bought 40.0K
| Insider | Stake change | Holds now | Granted / vested | Bought | Sold |
|---|---|---|---|---|---|
| Fell Donald G.Director · 4 transactions | — | 20.0Kas of Jun 2025 | — | 40.0K | — |
Select a row to see that insider’s individual transactions.
Net open-market activity over the last 3 years: +40.0K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.